Fernando Rivera

机构：Instituto de Investigación Marqués de Valdecilla

发表论文 50 篇 · 总被引 3768 次 · h-index 17

代表论文

• Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial (2018 · The Lancet · 被引 1326)
• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial (2023 · The Lancet Oncology · 被引 661)
• Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer (2025 · New England Journal of Medicine · 被引 265)
• Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry (2017 · British Journal of Cancer · 被引 106)
• Phase II study to evaluate the efficacy of Trastuzumab in combination with Capecitabine and Oxaliplatin in first-line treatment of HER2-positive advanced gastric cancer: HERXO trial (2019 · Cancer Chemotherapy and Pharmacology · 被引 66)
• Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab (2018 · The Oncologist · 被引 58)